Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

(2012) S. Kumar et al.   BLOOD

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

(2012) Z. Tian et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment

(2012) A. A. Chanan-Khan et al.   CLINICAL CANCER RESEARCH

Emerging biological insights and novel treatment strategies in multiple myeloma

(2012) Massimo Gentile et al.   EXPERT OPINION ON EMERGING DRUGS

The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma

(2012) Kenneth C. Anderson   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

(2012) M A Dimopoulos et al.   LEUKEMIA

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

(2011) E. C. Lee et al.   CLINICAL CANCER RESEARCH

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

(2011) Dharminder Chauhan et al.   CLINICAL CANCER RESEARCH

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Management of treatment-emergent peripheral neuropathy in multiple myeloma

(2011) P G Richardson et al.   LEUKEMIA

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

(2010) C. B. Reeder et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

(2010) María-Victoria Mateos et al.   LANCET ONCOLOGY

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

(2009) Sundar Jagannath et al.   BRITISH JOURNAL OF HAEMATOLOGY

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

(2008) Sagar Lonial et al.   BRITISH JOURNAL OF HAEMATOLOGY

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

(2008) Joseph R. Mikhael et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE